Navigation Links
Muslim Nations Urged To Address Health Needs

er states such as Malaysia, Iran and the United Arab Emirates have pledged $9 million to help fight polio and malaria in Sudan, Senegal and Yemen. He said Pakistan and Iran had also made progress in advanced research into drugs and vaccines. A donors' conference convened this week by the OlC in Doha, Qatar, pledged more than $360 million to Niger to help fight malnutrition.

One of the most feasible areas of collaboration is in halal vaccine production, said Badawi, adding that Malaysia has taken the lead in this regard by establishing the national institute as an agency in promoting self-sufficiency in the production of these vaccines. "We believe the development of halal vaccines would break new ground for promoting public health in Islamic nations," he said. With quality and safe halal vaccines being developed, Muslim communities would be more empowered to ensure their children are vaccinated, and fears of contamination and side effects would be eased.

Bearing the theme "Health _ the impetus towards Islamic solidarity" the international symposium is attended by health ministers and officials from the 56 countries under the OIC. Also participating are relevant international bodies such as the World Health Organization, Unicef, CDC-US and other OIC agencies.

The conference, which began June 12 and ends today (June 15), discussed a range of health-related issues of global concern, such as international health regulation, tobacco addiction, women and childrens' health, preparation for the Hajj season and preparedness for a pandemic influenza outbreak, among other things.


'"/>




Page: 1 2

Related medicine news :

1. Family planning is insisted upon Muslims by Shia cleric
2. AIDS bias successfully overcome by Indian Muslims in South Africa
3. Muslim Leaders’ Help Sought To Discourage Smokin
4. Muslims in Malaysia Banned from Using Botox
5. Muslim Leaders Urge Community to Join Anti-Polio Drive
6. Sexual Harassment on the Rise in Aligarh Muslim University
7. Burka Style Inter-faith Gowns For Muslim Patients In UK
8. Veils Banned to Muslim medicos in Birmingham Hospital
9. Muslim Clerics to Join Hands to Eradicate Polio
10. Separate and Specific Health Care Facilities for Muslims
11. Madhya Pradesh Begins Surya Namaskar Amid Muslim Opposition
Post Your Comments:
(Date:10/7/2008)...ty of life after discharge, study finds , ...edicine for intensive care unit (ICU) patients may...they,re able, a new report says. , Based on a ...ty School of Medicine researchers concluded that t...ause unnecessary and long-term physical impairment...
(Date:10/7/2008)...ely to enjoy better quality of life, study finds ,...nd-of-life discussions between a doctor and a term...for patients. In fact, they result in less aggress...life in a patient,s final days, a major new study ... has been around when, whether and how to have end...
(Date:10/7/2008)... -- Join Mii amo, a destination spa,at Enchantment...d rock,country honoring the winter solstice on Dec...al Native American ceremonies facilitated by Nativ...l guest, Elder George,Goodstriker., Goodstriker i...Reserve,in Standoff, Alberta, Canada,s largest res...
(Date:10/7/2008)...re/ -- Van Wert County Hospital, Van,Wert, Ohio, h...CARE(R),Corp.,s newest Emergency Department applic...al joins Conway Regional Medical Center, Conway,A..., Nashua, New Hampshire,in using OnRecord(TM) EDI... County Hospital began using OnRecord(TM) for all ...
Breaking Medicine News(10 mins):Health News:Early Mobility Best for ICU Patients 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 2Health News:Patients Benefit From End-of-Life Discussions With a Doctor 3Health News:Mii amo Honors Winter Solstice With Traditional Native American Celebration December 18-21 2Health News:Latest LOGICARE(R) EDIS User Sees 'Tremendous Results' 2
...a study published in the August issue of Neurology...ents are admitted to and discharged from the hospi...icantly. Studies have shown that several treatment...ount of disability, complications and the risk of ...
...a recent study researchers say that they found tha...te tumour cells in laboratory settings. Scientist...state cancer // could be due to a rapid increase i... the western diet in recent years. Omega-6 fats ha...
...shown that the efficacy of low-carb diets could be...chers question whether raising protein intake coul...esearchers set out to test the hypothesis that inc...bohydrate intake decreases the appetite, leads to ...
...he century started with a big bang, bringing hope ...ever, fate and nature had ideas of their own. 20...isasters and man made ones. The first internatio... February 1st in California when a jet bound for S...
Other Medicine News:Health News:Simple Procedural Improvements Can Improve Care Of Stroke Patients 2Health News:Finding The Key To Weight Loss! 2Health News:SARS (Bird Flu) spreading in the Asian continent 2
(Date:10/7/2008)...Prevented Immunologic Changes Induced by ...itional Data Indicates Potential in Treating Infla...ewswire/ -- Alba Therapeutics Corporation,presente...he American,College of Gastroenterology (ACG) 2008...001-004, the first Phase IIa trial conducted in ce...
(Date:10/7/2008)... ACG Annual Scientific Meeting -, ORLANDO, Fla., ...uticals, Inc. (formerly Microbia, Inc.) and Forest...the presentation of results from a Phase,2b study ... patients with,irritable bowel syndrome with const...at once- daily oral dosing of linaclotide, across ...
(Date:10/7/2008)...d Placebo-Controlled Phase II Study Shows ...al., MOUNTAIN VIEW, California, October 7 /PRNews...he mature Phase II data from the,therapeutic prost... been,obtained as part of the recently entered par...in the US., The results from the Phase II prospec...
(Date:10/7/2008)... /-, - 125 Patient, Prospe...,Shows Statistically Significant Improved Overall ...ature phase II data from the,therapeutic prostate ...n,obtained as part of the recently entered partner...he US., The results from the Phase II prospective...
Breaking Medicine Technology:Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 2Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 3Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 4Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 5Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting 6Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 2Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 3Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 4Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation 5BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 2Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 3Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 4Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine 5Cultures role on alcohol and violence 26970 1Cultures role on alcohol and violence 26970 2Forest Laboratories Inc Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 8032 1Forest Laboratories Inc Sets Date and Conference Call for Fiscal 2009 Second Quarter Earnings 8032 2Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 1Invest in Kids Rally to Be Held Before St Louis Vice Presidential Debate 26966 2The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 1The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 2The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 3The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 4The Scientific Business of Thomson Reuters Predicts Nobel Laureates 26962 5
...ire-FirstCall/ -,Neurochem (International) Limited...em Inc. , announces that the New England,Journal o...rodisate,For AA Amyloidosis Trial" (EFAAT), recogn...r a treatment of AA amyloidosis. The,results of th...TA(TM)) demonstrate that this product candidate of...
...007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today an... evaluating the company,s once-daily,anti-HIV drug...r,DF) 300 mg as a potential treatment for chronic ... efficacy endpoint. The study shows,that Viread is...l,drug Hepsera(R) (adefovir dipivoxil) among patie...
Other Medicine Technology:Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 2Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 3Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 4Landmark Study Published in the New England Journal of Medicine,Shows Important Benefits of Eprodisate (KIACTA) Treatment for,Patients with Amyloid A (AA) Amyloidosis 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 2Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 3Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 4Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 5Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 6Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint 7
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: